**Author details**

Chetan Chandola and Muniasamy Neerathilingam\* Department of Lipid Science, CSIR-Central Food Technological Research Institute, Mysore, India

\*Address all correspondence to: mneerathilingam@gmail.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**17**

*Aptamers for Targeted Delivery: Current Challenges and Future Opportunities*

[10] Raouane M, Desmaële D, Urbinati G, et al. Lipid conjugated oligonucleotides: A useful strategy for delivery. Bioconjugate Chemistry.

[11] Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Therapy.

[12] Xu Y, Szoka FC. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry. 1996;**35**:5616-5623

[13] Sakurai F, Nishioka T, Saito H, et al. Interaction between DNAcationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: The role of the neutral helper lipid. Gene Therapy.

[14] Lee CH, Lee SH, Kim JH, et al. Pharmacokinetics of a cholesterolconjugated aptamer against the hepatitis C virus (HCV) NS5B protein. Molecular Therapy. Nucleic Acids.

[15] Healy JM, Lewis SD, Kurz M, et al. Pharmacokinetics and biodistribution of novel aptamer

[17] Kuwahara M, Sugimoto N. Molecular evolution of functional nucleic acids with chemical modifications. Molecules.

compositions. Pharmaceutical Research.

[16] Yan X, Gao X, Zhang Z. Isolation and characterization of 2′-aminomodified RNA aptamers for human TNFalpha. Genomics, proteomics Bioinforma/Beijing Genomics Inst.

2012;**23**:1091-1104

2001;**8**:1188-1196

2001;**8**:677-686

2015;**4**:e254

2004;**21**:2234-2246

2004;**2**:32-42

2010;**15**:5423-5444

*DOI: http://dx.doi.org/10.5772/intechopen.84217*

[1] Ellington AD, Szostak J. In vitro selection of RNA molecules that bind specific ligands. Nature.

[2] Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to

Science. 1990;**249**:505-510

[3] Yoon S, Rossi JJ. Aptamers:

bacteriophage T4 DNA polymerase.

Uptake mechanisms and intracellular applications. Advanced Drug Delivery Reviews. 2018;**134**:22-35. DOI: 10.1016/j.

[4] Chandola C, Kalme S, Casteleijn MG, et al. Application of aptamers in diagnostics, drug-delivery and imaging. Journal of Biosciences. 2016;**41**:535-561

[5] Maier KE, Levy M. From selection hits to clinical leads: Progress in aptamer discovery. Molecular Therapy. Methods & Clinical Development.

[6] Yang JP, Huang L. Time-dependent maturation of cationic liposome-DNA complex for serum resistance. Gene

[7] Crook K, Stevenson BJ, Dubouchet M, et al. Inclusion of cholesterol in DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence of serum. Gene

[8] Li S, Tseng WC, Beer Stolz D, et al. Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: Implications for intravenous lipofection. Gene Therapy.

[9] Wheeler JJ, Palmer L, Ossanlou M, et al. Stabilized plasmid-lipid particles: Construction and characterization. Gene Therapy. 1999;**6**:271-281

**References**

1990;**346**:818-822

addr.2018.07.003

2016;**3**:16014

Therapy. 1998;**5**:380-387

Therapy. 1998;**5**:137-143

1999;**6**:585-594

*Aptamers for Targeted Delivery: Current Challenges and Future Opportunities DOI: http://dx.doi.org/10.5772/intechopen.84217*
